

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



自然美
natural beauty

Natural Beauty Bio-Technology Limited

自然美生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00157)

HOLDING ANNOUNCEMENT

Reference is made to the announcement of Natural Beauty Bio-Technology Limited (the “**Company**”) dated 31 August 2015 in relation to the suspension of trading of the Company’s shares (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pending the release by the Company of an announcement (the “**Announcement**”) containing inside information relating to the Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”).

The board of directors of the Company wishes to provide an update to the shareholders and potential investors of the Company regarding the latest development concerning the suspension of trading of the Shares.

The Company has been informed that, on 4 September 2015, Next Focus Holdings Limited (“**Next Focus**”) entered into an agreement to acquire (the “**Acquisition**”) the other 50% in the share capital of Starsign International Limited (“**Starsign**”) not already owned by it from CA NB Limited (“**CA NB**”). CA NB is an exempted company incorporated in the Cayman Islands with limited liability and is ultimately owned by Carlyle Asia Partners III, L.P., a Cayman Islands limited liability partnership that was launched in 2007. Next Focus is a company incorporated in the British Virgin Islands, which is ultimately held as to 40 per cent., 30 per cent. and 30 per cent. by each of Dr. Tsai Yen-Yu, Dr. Su Chien-Cheng and Dr. Su Sh Hsyu respectively. Each of Dr. Tsai Yen-Yu and Dr. Su Chien-Cheng is currently an executive director while Dr. Su Sh Hsyu is currently a non-executive director of the Company. If completion of the Acquisition takes place, Next Focus will own 100% of the share capital of Starsign, which controls approximately 65.63% of the share capital of the Company.

Subject to closing of the Acquisition taking place, Next Focus will make a mandatory general offer for all the Shares (other than those already owned or agreed to be acquired by Next Focus) then in issue pursuant to Note 8 of Rule 26.1 of the Takeovers Code.

The Company is currently in the process of preparing the Announcement. The Announcement will be published in accordance with the Rules Governing the Listing of Securities on the Stock Exchange and Takeovers Code by the Company as soon as practicable.

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 31 August 2015 and will remain suspended pending the release of the Announcement.

By order of the Board
Natural Beauty Bio-Technology Limited
Tsai Yen-Yu
Chairperson

Hong Kong, 9 September 2015

As at the date of this announcement, the Board comprises Dr. Tsai Yen-Yu, Mr. Lee Ming-Ta and Dr. Su Chien-Cheng as executive directors; Mr. Patrick Thomas Siewert, Dr. Su Sh-Hsyu, Mr. Gregory Michael Zeluck, Ms. Gong Zhizhi and Mr. Chang Hsiuguo as non-executive directors; and Mr. Francis Goutenmacher, Ms. Su-Mei Thompson, Mr. Chen Ruey-Long and Mr. Yang TzeKaing as independent non-executive directors.

The directors of the Company jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.